Berlin - Delayed Quote EUR
PTC Therapeutics Inc (BH3.BE)
43.00
-1.40
(-3.15%)
As of 7:37:05 PM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
806,780
806,780
937,822
698,801
538,593
Cost of Revenue
57,398
57,398
65,486
44,678
32,328
Gross Profit
749,382
749,382
872,336
654,123
506,265
Operating Expense
896,129
896,129
1,221,738
1,094,048
881,208
Operating Income
-146,747
-146,747
-349,402
-439,925
-374,943
Net Non Operating Interest Income Expense
-166,993
-166,993
-129,180
-90,871
-86,022
Other Income Expense
-49,379
-49,379
-217,528
-56,691
-57,375
Pretax Income
-363,119
-363,119
-696,110
-587,487
-518,340
Tax Provision
176
176
-69,506
-28,470
5,561
Net Income Common Stockholders
-363,295
-363,295
-626,604
-559,017
-523,901
Diluted NI Available to Com Stockholders
-363,295
-363,295
-626,604
-559,017
-523,901
Basic EPS
-5.94
-4.73
-8.37
-7.79
-7.43
Diluted EPS
-5.94
-4.73
-8.37
-7.79
-7.43
Basic Average Shares
76,411.69
76,845.06
74,838.39
71,728.63
70,466.39
Diluted Average Shares
76,411.69
76,845.06
74,838.39
71,728.63
70,466.39
Total Operating Income as Reported
-302,570
-302,570
-439,502
-447,409
-374,443
Total Expenses
953,527
953,527
1,287,224
1,138,726
913,536
Net Income from Continuing & Discontinued Operation
-363,295
-363,295
-626,604
-559,017
-523,901
Normalized Income
-240,194.83
-240,194.83
-421,711.80
-551,895.23
-524,266
Interest Expense
166,993
166,993
129,180
90,871
86,022
Net Interest Income
-166,993
-166,993
-129,180
-90,871
-86,022
EBIT
-196,126
-196,126
-566,930
-496,616
-432,318
EBITDA
-120,463
-120,463
-330,340
-367,780
-368,184
Reconciled Cost of Revenue
42,473
42,473
51,531
32,396
22,945
Reconciled Depreciation
75,663
75,663
236,590
128,836
64,134
Net Income from Continuing Operation Net Minority Interest
-363,295
-363,295
-626,604
-559,017
-523,901
Total Unusual Items Excluding Goodwill
-155,823
-155,823
-227,658
-7,484
500
Total Unusual Items
-155,823
-155,823
-227,658
-7,484
500
Normalized EBITDA
35,360
35,360
-102,682
-360,296
-368,684
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-32,722.83
-32,722.83
-22,765.80
-362.23
135
12/31/2021 - 6/20/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
87S.DU Roivant Sciences Ltd
9.51
+0.72%
6XC.BE Soleno Therapeutics Inc
64.00
-0.16%
ATQP.SG Vericel Corp
35.40
-0.56%
YDO1.BE Madrigal Pharmaceuticals Inc
268.40
+0.79%
ATQP.F Vericel Corporation
34.80
-1.69%
YDO1.F Madrigal Pharmaceuticals, Inc.
274.10
+0.77%
A71.F Ascendis Pharma A/S
138.00
-2.82%
GYRE Gyre Therapeutics, Inc.
9.05
-1.52%
VCEL Vericel Corporation
40.29
+0.60%
ASND Ascendis Pharma A/S
156.36
-1.13%